Benvitimod for the treatment of psoriasis: A systematic review and meta‐analysis of randomized controlled trials

医学 安慰剂 随机对照试验 特应性皮炎 不利影响 相对风险 内科学 银屑病 科克伦图书馆 荟萃分析 银屑病面积及严重程度指数 湿疹面积及严重程度指数 临床试验 皮肤科生活质量指数 临床终点 置信区间 物理疗法 皮肤病科 替代医学 病理
作者
Muhammad Ehsan,Aqeeb Ur Rehman,Farwa Athar,Biah Mustafa,Haseeba Javed,Huzaifa Ahmad Cheema,Muhammad Ayyan,Abia Shahid,Uzair Jafar,Mohamad Goldust
出处
期刊:Dermatologic Therapy [Wiley]
卷期号:35 (12) 被引量:2
标识
DOI:10.1111/dth.15957
摘要

Benvitimod is a topical drug that has recently been approved for mild to moderate psoriasis and atopic dermatitis. The drug has just completed phase 3 trials for psoriasis, which calls for a systematic update of current evidence on the efficacy and safety of this drug. We searched MEDLINE (PubMed), EMBASE, Science Direct, International Clinical Trials Registry Platform (ICTRP), Cochrane Central Register of Controlled Trials, and Google Scholar for all available randomized controlled trials concerning the topic. We included six randomized controlled trials evaluating the efficacy of benvitimod 1.0% with a total of 1925 patients. Our meta-analysis demonstrated that more patients in the benvitimod group achieved physician global assessment score of 0 or 1 (RR 6.53, 95% CI 4.39–9.71), psoriasis area and severity index (PASI) 75 (RR 4.34, 95% CI 2.96–6.36), PASI 90 (RR 8.83, 95% CI 5.22–14.95) and body surface area reduction (MD −3.85, 95% CI −4.83, −2.88) than placebo at week 12. Patient-reported outcomes were also analyzed, yielding a significant benefit in the benvitimod group for peak pruritus numerical rating scale (PP-NRS) score (MD −1.20, 95% CI −1.98, −0.42), ≥4-point decrease in PP-NRS score (RR 1.58, 95% CI, 1.24–2.03) and dermatology life quality index score (MD −2.54, 95% CI −4.00, −1.07). There was a significantly higher incidence of adverse events in the benvitimod group compared to placebo (RR 1.98, 95% CI 1.73–2.27), while the risk was found to be non-significant for serious adverse events. Benvitimod is an effective treatment of psoriasis as compared to a placebo. However, more large-scale, high-quality trials are needed to comment on the safety of this drug.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阳光发布了新的文献求助10
刚刚
半夏发布了新的文献求助10
1秒前
2秒前
3秒前
Miracle_wh完成签到,获得积分10
3秒前
4秒前
Miracle_wh发布了新的文献求助10
6秒前
8秒前
8秒前
9秒前
9秒前
圆月弯刀完成签到 ,获得积分10
10秒前
坦率白萱应助DJANGO采纳,获得30
12秒前
露亮完成签到,获得积分10
13秒前
Bressanone发布了新的文献求助10
13秒前
14秒前
斯文的慕儿完成签到 ,获得积分10
16秒前
露亮发布了新的文献求助10
16秒前
16秒前
智慧少女不头秃完成签到,获得积分10
18秒前
33完成签到,获得积分10
19秒前
所所应助感谢有你采纳,获得10
21秒前
21秒前
22秒前
23秒前
乐乐应助anna采纳,获得10
26秒前
潇湘雪月发布了新的文献求助10
26秒前
26秒前
刘燕发布了新的文献求助10
27秒前
27秒前
28秒前
量子星尘发布了新的文献求助10
31秒前
俏皮芷蕊发布了新的文献求助10
31秒前
32秒前
35秒前
35秒前
36秒前
Rondab应助张学友采纳,获得10
39秒前
39秒前
anna发布了新的文献求助10
40秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136